← Back to Clinical Trials
Recruiting NCT06815302

NCT06815302 TURN-IT FOG: Improving Turning and Freezing of Gait in People With PD

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06815302
Status Recruiting
Phase
Sponsor Oregon Health and Science University
Condition Parkinson Disease
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2025-06-02
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Experimental interventionActive intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2025-06-02 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goals of this clinical trial are to 1) learn how two different rehabilitation interventions for PD can reduce Freezing of Gait (FOG) in people with Parkinson's disease, as assessed by patients, clinicians, and wearable sensors, and 2) to explore whether two different rehabilitation intervention can reduce FOG and improve daily life mobility in people with FOG sufficiently to justify a clinical trial. Participants will: * Be randomly assigned to one of two intervention groups (turning-focused agility exercise or strength-based exercise) * Have one-on-one training sessions three times per week for 6 weeks * Perform in-lab assessments before beginning and after completing the study intervention * Use wearable mobility sensors during daily life to measure their walking and balance

Eligibility Criteria

Inclusion Criteria: * diagnosis of idiopathic PD from movement disorders neurologist with the United Kingdom Brain Bank criteria of bradykinesia with one or more of the following - rest tremor, rigidity, and balance problems not from visual, vestibular, cerebellar or proprioceptive conditions * reporting FOG in the New Freezing of Gait questionnaire (N-FOGQ) * Hoehn \& Yahr stages II-IV * ages 50-80 years old * cognitive ability sufficient to participate in testing procedures and exercise classes * be willing and able to participate in exercise intervention 3x/week for 6 weeks Exclusion Criteria: * Major musculoskeletal or neurological disorders, structural brain disease, epilepsy, acute illness or health history, other than PD, significantly affecting gait and turning (i.e., musculoskeletal disorder, vestibular problem, head injury, stroke, cardiac disease) * medical condition or medications that precludes moderate-intensity exercise * Montreal Cognitive Assessment (MoCA) ≤21 or inability to follow directions * excessive use of alcohol or recreational drugs * recent change in medication * inability to stand and walk for 2 minutes without an assistive device

Contact & Investigator

Central Contact

Graham R Harker, MPH

✉ harkerg@ohsu.edu

📞 (503) 418-2601

Principal Investigator

Martina Mancini, PhD

PRINCIPAL INVESTIGATOR

Oregon Health and Science University

Frequently Asked Questions

Who can join the NCT06815302 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, up to 80 Years, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06815302 currently recruiting?

Yes, NCT06815302 is actively recruiting participants. Contact the research team at harkerg@ohsu.edu for enrollment information.

Where is the NCT06815302 trial being conducted?

This trial is being conducted at Tempe, United States, Portland, United States, Bauru, Brazil.

Who is sponsoring the NCT06815302 clinical trial?

NCT06815302 is sponsored by Oregon Health and Science University. The principal investigator is Martina Mancini, PhD at Oregon Health and Science University. The trial plans to enroll 60 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology